Fezolamine (Win-41,528-2) is a drug which was investigated by Sterling Drug as an antidepressant in the 1980s.[1][2] The isomeric N,N-dimethyl-4,5-diphenyl-1H-pyrazole-1-propanamine was completely inactive in the primary antidepressant screens.
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H23N3 |
| Molar mass | 305.425 g·mol−1 |
| 3D model (JSmol) | |
| |
It acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor, with 3- to 4-fold preference for the former neurotransmitter.[3] It was found to be effective and well tolerated in clinical trials but was never marketed.[4]
See also
editReferences
edit- ^ U.S. patent 4,182,895
- ^ Bailey DM, Hansen PE, Hlavac AG, Baizman ER, Pearl J, DeFelice AF, Feigenson ME (February 1985). "3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants". Journal of Medicinal Chemistry. 28 (2): 256–60. doi:10.1021/jm00380a020. PMID 3968690.
- ^ Baizman ER, Ezrin AM, Ferrari RA, Luttinger D (October 1987). "Pharmacologic profile of fezolamine fumarate: a nontricyclic antidepressant in animal models". The Journal of Pharmacology and Experimental Therapeutics. 243 (1): 40–54. PMID 3668867.
- ^ Zisook S, Mendels J, Janowsky D, Feighner J, Lee JC, Fritz A (1987). "Efficacy and safety of fezolamine in depressed patients". Neuropsychobiology. 17 (3): 133–8. doi:10.1159/000118353. PMID 3683802.